
|Videos|July 7, 2015
Impact of a Stage IV NSCLC Care Pathway on Frontline and Maintenance Chemotherapy Use
Author(s)James Stevenson, MD
James Stevenson, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the impact of a stage IV non-small cell lung cancer (NSCLC) care pathway on frontline and maintenance chemotherapy use.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
5








































